Literature DB >> 28725652

Rescuing BMPR2-driven endothelial dysfunction in PAH: a novel treatment strategy for the future?

Rozenn Quarck1, Fréderic Perros2.   

Abstract

Entities:  

Year:  2017        PMID： 28725652      PMCID： PMC5503913          DOI： 10.21037/sci.2017.05.11

Source DB:  PubMed          Journal:  Stem Cell Investig        ISSN： 2306-9759


× No keyword cloud information.
  15 in total

1.  LRP1-dependent endocytic mechanism governs the signaling output of the bmp system in endothelial cells and in angiogenesis.

Authors:  Xinchun Pi; Christopher E Schmitt; Liang Xie; Andrea L Portbury; Yaxu Wu; Pamela Lockyer; Laura A Dyer; Martin Moser; Guojun Bu; Edward J Flynn; Suk-Won Jin; Cam Patterson
Journal:  Circ Res       Date:  2012-07-09       Impact factor: 17.367

2.  Bone morphogenetic protein receptor type II and inflammation are bringing old concepts into the new pulmonary arterial hypertension world.

Authors:  Frédéric Perros; Sébastien Bonnet
Journal:  Am J Respir Crit Care Med       Date:  2015-10-01       Impact factor: 21.405

Review 3.  Bone morphogenetic protein type II receptor mutations causing protein misfolding in heritable pulmonary arterial hypertension.

Authors:  Wei Li; Benjamin J Dunmore; Nicholas W Morrell
Journal:  Proc Am Thorac Soc       Date:  2010-11

4.  Harvest of pulmonary artery endothelial cells from patients undergoing right heart catheterization.

Authors:  Jonathan B Pollett; Raymond L Benza; Srinivas Murali; Kelly J Shields; Michael J Passineau
Journal:  J Heart Lung Transplant       Date:  2013-05-15       Impact factor: 10.247

Review 5.  Inflammation in pulmonary arterial hypertension.

Authors:  Laura C Price; S John Wort; Frédéric Perros; Peter Dorfmüller; Alice Huertas; David Montani; Sylvia Cohen-Kaminsky; Marc Humbert
Journal:  Chest       Date:  2012-01       Impact factor: 9.410

Review 6.  Updated clinical classification of pulmonary hypertension.

Authors:  Gerald Simonneau; Michael A Gatzoulis; Ian Adatia; David Celermajer; Chris Denton; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; R Krishna Kumar; Michael Landzberg; Roberto F Machado; Horst Olschewski; Ivan M Robbins; Rogiero Souza
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

Review 7.  Use of β-Blockers in Pulmonary Hypertension.

Authors:  Frédéric Perros; Frances S de Man; Harm J Bogaard; Fabrice Antigny; Gérald Simonneau; Sébastien Bonnet; Steeve Provencher; Nazzareno Galiè; Marc Humbert
Journal:  Circ Heart Fail       Date:  2017-04       Impact factor: 8.790

8.  Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension.

Authors:  L Dewachter; S Adnot; C Guignabert; L Tu; E Marcos; E Fadel; M Humbert; P Dartevelle; G Simonneau; R Naeije; S Eddahibi
Journal:  Eur Respir J       Date:  2009-03-26       Impact factor: 16.671

9.  Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension.

Authors:  Edda Spiekerkoetter; Yon K Sung; Deepti Sudheendra; Matthew Bill; Micheala A Aldred; Mariëlle C van de Veerdonk; Anton Vonk Noordegraaf; Janel Long-Boyle; Rajesh Dash; Phillip C Yang; Allan Lawrie; Andrew J Swift; Marlene Rabinovitch; Roham T Zamanian
Journal:  Am J Respir Crit Care Med       Date:  2015-07-15       Impact factor: 21.405

Review 10.  Genetics and genomics of pulmonary arterial hypertension.

Authors:  Florent Soubrier; Wendy K Chung; Rajiv Machado; Ekkehard Grünig; Micheala Aldred; Mark Geraci; James E Loyd; C Gregory Elliott; Richard C Trembath; John H Newman; Marc Humbert
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094
View more
  6 in total

1.  Targeting epigenetic mechanisms as an emerging therapeutic strategy in pulmonary hypertension disease.

Authors:  Malik Bisserier; Radoslav Janostiak; Frank Lezoualc'h; Lahouaria Hadri
Journal:  Vasc Biol       Date:  2020-01-09

Review 2.  Endothelial Dysfunction in Pulmonary Hypertension: Cause or Consequence?

Authors:  Kondababu Kurakula; Valérie F E D Smolders; Olga Tura-Ceide; J Wouter Jukema; Paul H A Quax; Marie-José Goumans
Journal:  Biomedicines       Date:  2021-01-09

3.  An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension.

Authors:  Gusty R T Ryanto; Koji Ikeda; Kazuya Miyagawa; Ly Tu; Christophe Guignabert; Marc Humbert; Tomoyuki Fujiyama; Masashi Yanagisawa; Ken-Ichi Hirata; Noriaki Emoto
Journal:  Nat Commun       Date:  2021-03-19       Impact factor: 14.919

4.  Incremental Experience in In Vitro Primary Culture of Human Pulmonary Arterial Endothelial Cells Harvested from Swan-Ganz Pulmonary Arterial Catheters.

Authors:  Birger Tielemans; Leanda Stoian; Allard Wagenaar; Mathias Leys; Catharina Belge; Marion Delcroix; Rozenn Quarck
Journal:  Cells       Date:  2021-11-19       Impact factor: 6.600

Review 5.  Therapeutic Approaches for Treating Pulmonary Arterial Hypertension by Correcting Imbalanced TGF-β Superfamily Signaling.

Authors:  Patrick Andre; Sachindra R Joshi; Steven D Briscoe; Mark J Alexander; Gang Li; Ravindra Kumar
Journal:  Front Med (Lausanne)       Date:  2022-01-24

Review 6.  Epigenetic Mechanisms as Emerging Therapeutic Targets and Microfluidic Chips Application in Pulmonary Arterial Hypertension.

Authors:  Linh Ho; Nazir Hossen; Trieu Nguyen; Au Vo; Fakhrul Ahsan
Journal:  Biomedicines       Date:  2022-01-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.